LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Early Detection Blood Test Could Transform Diagnosis and Treatment of Alzheimer's

By LabMedica International staff writers
Posted on 15 Aug 2023
Image: Researchers are working towards a ‘transformative’ early blood test for Alzheimer’s (Photo courtesy of Freepik)
Image: Researchers are working towards a ‘transformative’ early blood test for Alzheimer’s (Photo courtesy of Freepik)

Alzheimer's disease is a slowly progressive neurodegenerative disorder that becomes worse over time and accounts for 60-70% of all cases of dementia. Recent findings suggest that changes can take place in the brains of individuals with Alzheimer's before any noticeable symptoms appear. Now, a new blood test could transform the ability of clinicians to diagnose Alzheimer’s much in advance of any visible symptoms.

Roche Diagnostics (Basel, Switzerland) and Scottish Brain Sciences (Edinburgh, Scotland) have joined forces for a series of major projects focused on improving understanding of the earliest biological changes related to neurodegenerative diseases, using blood-based biomarkers. The aim is to be able to characterize and identify these changes that could result in accurate early diagnostic tests, potentially facilitating faster treatment for patients. Diagnosing Alzheimer's at an earlier stage could also help delay residential care and cut down costs related to health and social care.

In July, a global trial confirmed that a drug named donanemab was effective in slowing down cognitive decline in Alzheimer's patients. This antibody medicine was found to be most effective during the initial phases of the disease by eliminating a protein that accumulates in the brain. The study revealed that those in the early stages of the disease experienced the maximum benefits from the treatment. Efforts aimed at early intervention during the preliminary phases of Alzheimer's could prevent late-stage dementia syndromes related to neurodegenerative diseases. The collaboration between Roche and Scottish Brain Sciences guarantees that any blood tests developed through the partnership will be accessible to individuals impacted by the debilitating condition. The potential to identify Alzheimer's disease in its nascent stages could result in improved patient outcomes, the advancement of research, and reduced burden on healthcare systems.

Related Links:
Roche Diagnostics
Scottish Brain Sciences 

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more